IAIM
KRYS icon

International Assets Investment Management’s Krystal Biotech KRYS Stock Holding History

International Assets Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97K Buy
8
+4
+100% +$1.2K ﹤0.01% 2072
2026
Q1 		$1.04K Buy
+4
New +$1.06K ﹤0.01% 2062

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

International Assets Investment Management's KRYS Position: Q2 2026 in Review

International Assets Investment Management increased its Krystal Biotech (KRYS) stake by 100% in Q2 2026, buying an estimated $1.2K and bringing the position to 8 shares worth $2.97K. The position accounts for ﹤0.01% of the portfolio, ranked #2072.

International Assets Investment Management first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • International Assets Investment Management held 8 shares of Krystal Biotech worth $2.97K as of Q2 2026.
  • International Assets Investment Management bought 4 Krystal Biotech shares in Q2 2026, an estimated $1.2K.
  • Krystal Biotech made up ﹤0.01% of International Assets Investment Management's portfolio in Q2 2026, its #2072 holding.
  • International Assets Investment Management first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.